See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic that is primarily used to treat infections caused by drug-resistant bacteria [1]. It is a glycylcycline antibiotic, which is a class of drugs that is derived from tetracyclines [1]. Tigecycline is effective against a wide range of gram-positive, gram-negative, and anaerobic bacteria [1].

Tigecycline is commonly used to treat complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [1]. It is also used to treat infections caused by multi-drug resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) [1].

According to DrugPatentWatch.com, tigecycline is currently marketed under the brand name Tygacil by Wyeth Pharmaceuticals, a subsidiary of Pfizer [2]. Tigecycline was approved by the US Food and Drug Administration (FDA) in 2005 [1].

In summary, tigecycline is a broad-spectrum antibiotic that is primarily used to treat infections caused by drug-resistant bacteria, including MRSA and VRE. It is effective against a wide range of gram-positive, gram-negative, and anaerobic bacteria.

Sources:

1. [Tigecycline: MedlinePlus Drug Information](https://medlineplus.gov/druginfo/meds/a608045.html)
2. [Tygacil (tigecycline) Drug Profile - DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/tygacil)